News|Articles|March 28, 2024

Neuromodulation for Depressive Disorders: Top 5 Takeaways

Our March CME reviews the principles and applications of invasive and noninvasive neuromodulation techniques for the treatment of mood disorders. Here are 5 key takeaways.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ByLeah Kuntz,AJ Cannon, MD

June 10th 2026

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

ByAmit Etkin, MD, PhD

June 9th 2026

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ByLeighann Forbes, PhD

June 8th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

Research Frontiers in Ketamine and Esketamine for Treatment-Resistant Depression

ByMorgan Hardy, MD,William Li, MD

June 2nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Neuromodulation for Depressive Disorders: Top 5 Takeaways

Related Content

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Research Frontiers in Ketamine and Esketamine for Treatment-Resistant Depression

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Monoamines: A Full House

Paying Attention to the Psychopharmacology Pipeline

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings